Full Press Release Details
linvoseltamab receives ema filing acceptance for treatment of relapsed refractory multiple myeloma.
REGN
linvoseltamab receives ema filing acceptance for treatment of relapsed refractory multiple myeloma
Key Takeaway: linvoseltamab receives ema filing acceptance for treatment of relapsed refractory multiple myeloma